Searchable abstracts of presentations at key conferences in endocrinology

ea0086p97 | Neuroendocrinology and Pituitary | SFEBES2022

Aberrant cyclic GMP-AMP synthase stimulator of interferon genes signalling in an AIP mutant cell line

Benjamin Loughrey Paul , Suleyman Oniz , Begalli Federica , Craig Stephanie G , Hunter Steven J , McArt Darragh G , James Jacqueline A , Haworth Oliver , Barry Sayka , Korbonits Marta

Background: The cyclic GMP-AMP synthase stimulator of interferon genes (cGAS-STING) signalling pathway is an element of the innate immune response and is activated by the presence of DNA in the cytosol. Triggering of this immune response may occur in the setting of infection or neoplasia. Activation of this pathway results in phosphorylation of interferon regulatory factor 3 and downstream transcription of cytokines such as interferon β and interleukin-6. Polyinosinic:pol...

ea0077p212 | Neuroendocrinology and Pituitary | SFEBES2021

Cabergoline treatment in human primary non-functioning pituitary adenomas

Begalli Federica , Komagata Tatsuya , Suleyman Oniz , Magid Kesson , Rice Thomas , Collier David , Dorward Neil , Grieve Joan , Mendoza Nigel , Nair Ramesh , Kolias Angelos , Khan Danyal , Marcus Hani J , Botta Joaquin , McCormick Peter J , Shinozaki Koji , Korbonits Marta

Non-functioning pituitary adenomas (NFPAs) are the second most common subtype (15-43%) of all clinically presenting pituitary adenomas. Although the primary treatment of symptomatic NFPAs is surgery, gross total resection is achieved only in about 66% of the cases, and 20% of gross total resected tumours recur after 10 years. Despite recent advances in medical management of pituitary tumours, NFPAs remain the only subtype with no widely accepted pharmacological treatment. Expr...

ea0094oc3.1 | Neuroendocrinology and Pituitary | SFEBES2023

CDC42: a potential therapeutic target of clinically non-functioning pituitary neuroendocrine tumours

Rai Ashutosh , Begalli Federica , Barry Sayka , Rice Thomas , Magid Kesson , Suleyman Oniz , Dorward Neil , Grieve Joan , Kolias Angelos , Khan Danyal , J Marcus Hani J. , Radotra Bishan D. , Chhabra Rajesh , Dhandapani S S. , Tripathi Manjul , Ahuja Chirag K. , Dutta Pinaki , Korbonits Marta

Background: There is no effective medical treatment available for non-functioning pituitary neuroendocrine tumours (NF-PitNETs). Recurrence (7-12%) or incomplete resection (30-45%) is a common feature. Thus, finding novel medical therapies to help the management of these tumours would be of great value. By using high-throughput mass spectrometry combined with functional characterisation, we explored novel therapeutic targets for NF-PitNETs.<p class="abstex...